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Abstract
We investigate the surgical outcomes of patients undergoing hepatectomy according to different age intervals, identify the clinical
factors related to surgical outcomes, and propose clinical risk scores for severe morbidity and mortality based on the clinical factors.
Eight hundred three patients undergoing liver resection were divided into 3 groups: young patients (YP), <65 years (n=387),
elderly patients (EP), from 65 to 74 years (n=279); very-elderly patients (VEP), ≥75 years (n=137).
Severe morbidity was 10.6%, 12.2%, and 17.5% (P= .103), and mortality was 0.3%, 1.4%, and 4.4% (P= .002) in group YP, EP,
and VEP, respectively. Ischemic heart disease, cirrhosis, major hepatectomy, biliary tract-associated procedure, and red blood cells
(RBC) transfusion ≥3U were related with severe morbidity. Ischemic heart disease, cirrhosis, major hepatectomy, and RBC
transfusion were independent risk factors for postoperative mortality. Age did not result an independent factor related tomortality and
severe morbidity. Two different scores were developed and have proved to be statistically related with severe morbidity andmortality.
Moreover, in patients with score ≥2, severe morbidity increased from 24.2% in YP, to 29.3% in EP, and to 40.0% in VEP, P= .047.
Likewise, mortality increased from 2.3% in YP, to 7.0% in EP, and to 22.7% in VEP, in patients with score ≥2, P= .017.
Age alone should not be considered a contraindication for hepatectomy. We identiﬁed factors and proposed 2 scores that can be
useful to stratify the risk of morbidity and mortality after hepatectomy. Moreover, severe morbidity and mortality increases according
to the different age intervals in patients with scores ≥2.
Abbreviations: ACS = acute coronary syndrome, ASA = American Society of Anaesthesiologists, AUC = area under the curves,
BMI = body mass index, CCA = cholangiocarcinoma, CCI = Charlson comorbidity index, CE-US = contrast-enhanced
ultrasonography, CRLM = colorectal liver metastases, CT = computed tomography, EP = elderly patients, GBC = gallbladder
cancer, HB = hepatobiliary, HCC = hepatocellular carcinoma, ICG = indocyanine green, MRI =magnetic resonance imaging, MS =
Mortality Score, NCRLM = noncolorectal liver metastases, PHLF = posthepatectomy liver failure, RBC = red blood cells, ROC =
receiver operating characteristic, SMS = Severe Morbidity Score, US = ultrasonography, VEP = very-elderly patients, YP = young
patients.
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1. Introduction surgery. Elderly patients (EP), in particular, are expected to have a
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1higher risk of postoperative complications. However, recent
improvements in theperioperativemanagementof liver surgeryhave
increased its safety.[3] Several studies investigated the outcomes of
liver resection in EP. Apparently,minor liver resections can be safely
performed. In EP undergoing major hepatectomy, future remnant
liver volume and liver function remain the most important factors
regarding short-term outcomes.[2,4]
Across the literature, there are different age cut-off values for
the deﬁnition of elderly, ranging from 65 to 80 years. However, in
most studies, the cut-off age is 70 years.[5–12] A signiﬁcant
reduction in liver mass and portal blood ﬂow were demonstrated
in patients aged 70 years or older,[13] but liver regeneration does
not seem to be signiﬁcantly affected by age.[14]
In recent years, eastern clinical studies of liver surgery in
patients older than 75 years have increased signiﬁcantly, and the
short-term results reported between elderly and younger patients
were similar.[11,15,16] In contrast, a western study reported an
increase in the complication rate in elderly population.[17]
Several clinical risk scores, including age and other periopera-
tive factors, have been proposed as predictors of the outcome of
patients undergoing surgery. Despite clinical studies demonstrat-
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practice is limited. The high number of variables taken into
account and the complexity are the major limitation for their
application.[18–20] Therefore, the aims of this study were: to
compare the clinical characteristics and surgical outcomes of
patients who underwent liver resection according to different age
intervals; to identify the clinical factors related with increased risk
of postoperative morbidity and mortality; to propose a clinical
score useful in the stratiﬁcation of postoperative risk of morbidity
and mortality based on the clinical factors identiﬁed and to apply
it in different age intervals.2. Patients and methods
2.1. Study population and data collection
All consecutive patients who underwent liver resection with
curative intent in a European high-volume tertiary referral
hepatobiliary (HB) centre between January 2006 and January
2015 were included in the study. Data were retrieved from a
prospectively collected database, and this analysis was performed
retrospectively. The ethical standards of the World Medical
Association (Declaration of Helsinki) were followed during the
conduction of this study.
The study population was divided into 3 groups: young
patients (YP), patients aged<65 years; EP, patients aged between
65 and 74 years; and very-elderly patients (VEP), patients aged 75
years or older.
Our study population included both patients with malignan-
cies, such as colorectal liver metastases (CRLM), hepatocellular
carcinoma (HCC), cholangiocarcinoma (CCA), noncolorectal
liver metastases (NCRLM), and gallbladder cancer (GBC), and
those with benign liver disease or other rare liver tumors.
The indication for surgery was made after a multidisciplinary
team discussion, including experienced HB surgeons, anesthesi-
ologists, gastroenterologists, hepatologists, oncologists, and
radiologists. Age was not considered per se as a selection
criterion for the type of treatment. Preoperative staging imaging
techniques included computed tomography (CT), magnetic
resonance imaging (MRI), ultrasonography (US), and contrast-
enhanced ultrasonography (CE-US) as appropriate. Preoperative
patient investigations included electrocardiogram, chest radiog-
raphy, and blood samples for all patients (hemoglobin, platelets,
bilirubin, aspartate aminotransferase, alanine aminotransferase,
gamma glutamyl transferase, sodium, creatinine, albumin, and
prothrombin time-international normalized ratio). In selected
cases, experienced cardiologists performed a complete clinical
and instrumental cardiac examination. Indocyanine green (ICG)
test was performed in selected patients with liver disease and
those who were candidates for major procedures.
The collected clinical data included age, sex, body mass index
(BMI), HCV or HBV infection, alcohol abuse (consumption ≥40
g/day), liver cirrhosis, and presence of comorbidities (hyperten-
sion, ischemic heart disease, type II diabetes, chronic obstructive
pulmonary disease, asthma, and chronic renal failure). The
American Society of Anaesthesiologists (ASA) score was applied
to evaluate the surgical risk for each patient. Charlson
comorbidity index (CCI) was calculated based on comorbidity
and diagnosis; all patients with liver resectable malignancies,
primary or secondary, were awarded 2 points. Patients with
diffuse metastatic disease were awarded 6 points.[21]
During surgery, intraoperative ultrasound was routinely
performed to conﬁrm preoperative diagnosis and to evaluate2the relationship between lesions, blood vessels, and biliary ducts.
Intraoperative vascular control of in-ﬂow and out-ﬂow was
achieved either by a selective clamping or by Pringle’s maneuver.
The transection of liver parenchyma was performed with
ultrasonic aspirator and selective ligation of all identiﬁable
vessels.
The extent of liver resection was classiﬁed according to the
Brisbane 2000 terminology.[22] In case of malignancies, curative
liver resection was deﬁned as the removal of all the recognizable
tumors. Complete tumor removal was conﬁrmed by histopathol-
ogy. Associated procedures were deﬁned as the resection of at
least one further organ and were classiﬁed according to the organ
resected as colon, rectum, common bile duct, major vessels
(portal vein, cava vein, and hepatic artery), pancreas, or other
organs.
Postoperative complications were assessed according to the
Clavien-Dindo classiﬁcation,[23] and divided into liver-related
and nonliver-related (pulmonary and cardiovascular) complica-
tions.
Additionally, the following speciﬁc liver complications were
recorded: posthepatectomy liver failure (PHLF), biliary ﬁstula,
ascites, abdominal collections, sepsis, and acute renal failure. A
PHLF was deﬁned according to the “ﬁfty-ﬁfty” criteria or
postoperative peak of serum bilirubin concentration >7mg/
dL.[24,25] Thirty-day mortality was deﬁned as death within 30
days after surgery; 90-day/in-hospital mortality was deﬁned as
death within 90 days after surgery or during the hospital stay and
was considered for the univariate and multivariate analysis.2.2. Statistical analysis
The study data were prospectively collected and analyzed using
SPSS statistical software (version 20.0; SPSS, Inc., Chicago, IL).
The Fisher exact or Pearson square tests were used for categorical
variables and the Student t test or 1-way ANOVA was used for
continuous variables where appropriate. The results were
expressed as mean and standard deviation (SD) or median and
range. Independent risk factors for severe morbidity and 90-day/
in-hospital mortality resulted from a multivariate logistic
regression model; the selection criteria for entering variables
into multivariate analysis was a P-value <.05 at univariate
analysis. To identify the clinical role of increasing in age, the age
variable categorized into the 3 groups (YP, EP, VEP) entered into
the multivariate analysis also with a P-value >.05. The P-
value< .05 was regarded as statistically signiﬁcant. Variables
identiﬁed at the multivariate analysis for both severe morbidity
and 90-day/in-hospital mortality were chosen to built a score for
severe morbidity (Severe Morbidity Score, SMS) and for
mortality (Mortality Score, MS), respectively. The scores were
calculated assigning one point for the presence each predictive
variable. Receiver operating characteristic (ROC) curves were
generated and the area under the curves (AUC) calculated to test
the predictive ability of SMS and MS, respectively.3. Results
3.1. Demographics and preoperative characteristics
A total of 803 patients were included in the present study. Of
these, 387 were younger than 65 years (YP, 48.2%), 279 were
between 65 and 74 years (EP, 34.7%), and 137 were 75 years or
older (VEP, 17.1%). Demographics and preoperative character-
istics of the study population are summarized in Table 1.
Table 1
Preoperative characteristics.
Total
(n=803), n (%)
<65 years (YP)
(n=387), n (%)
65–74 years (EP)
(n=279), n (%)
≥75 years (VEP)
(n=137), n (%) P
Age, median (range) 65.54 (11.16–92.98) 56.59 (11.16–64.99) 69.68 (65.00–74.91) 78.51 (75.00–92.98) <.001
Males 489 (60.9) 215 (55.6) 190 (68.1) 84 (61.3) .003
Body mass index, median (range) 25.2 (15.4–44.4) 24.7 (15.4–38.6) 25.8 (16.2–44.4) 25.7 (18.1–40.0) .005
Any comorbidities 610 (76.0) 246 (63.6) 237 (84.9) 127 (92.7) <.001
Comorbidities number, mean±SD 1.50±1.31 1.08±1.15 1.78±1.31 2.12±1.36 <.001
Hypertension 361 (45.0) 105 (27.1) 159 (57.0) 97 (70.8) <.001
Ischemic heart disease 68 (8.5) 20 (5.2) 27 (9.7) 21 (15.3) .001
Type II diabetes 191 (23.8) 57 (14.7) 87 (31.2) 47 (34.3) <.001
Pulmonary comorbidities 46 (5.7) 14 (3.6) 23 (8.2) 9 (6.6) .033
Chronic renal failure 15 (1.9) 8 (2.1) 3 (1.1) 4 (2.9) .339
Cirrhosis 109 (13.8) 40 (10.7) 42 (15.1) 27 (19.9) .021
HCV infection 63 (7.9) 25 (6.5) 25 (9.0) 13 (9.5) .371
HBV infection 68 (8.5) 36 (9.4) 27 (9.7) 5 (3.6) .078
Alcohol abuse 164 (20.4) 72 (18.6) 63 (22.6) 29 (21.2) .442
CCI≥3 326 (40.4) 107 (27.6) 140 (50.2) 79 (57.7) <.001
ASA score≥3 242 (30.1) 54 (14.0) 90 (32.3) 98 (71.5) <.001
ICG R15, median (range) 6.15 (0.5–45.8) 4.55 (0.5–27.1) 6.30 (1.3–45.8) 8.95 (2.0–40.1) .178
Malignant Disease 700 (87.2) 312 (80.6) 263 (94.3) 125 (91.2) <.001
CRLM 279 (34.7) 148 (38.2) 97 (34.8) 34 (24.8) .019
HCC 176 (21.9) 57 (14.7) 68 (24.4) 51 (37.2) <.001
CCA 162 (20.2) 57 (14.7) 73 (26.2) 32 (23.4) .001
GBC 28 (3.5) 15 (3.9) 9 (3.2) 4 (2.9) .902
NCRLM 52 (6.5) 34 (8.8) 14 (5.0) 4 (2.9) .029
Benign disease 103 (12.8) 75 (19.4) 16 (5.7) 12 (8.8) <0.001
Other malignant disease 3 (0.4) 1 (0.3) 2 (0.7) 0 (0.0) .758
ASA score=American Society of Anesthesiologists’ score, CCA= cholangiocarcinoma, CCI=Charlson comorbidity index, CRLM= colon-rectal liver metastases, EP= elderly patients, GBC=gallbladder cancer,
HBV=hepatitis B virus, HCC=hepatocellular carcinoma, HCV=hepatitis C virus, ICG R15= indocyanine green retention rate after 15minutes, NCRLM=noncolon-rectal liver metastases, SD= standard
deviation, VEP= very-elderly patients, YP= young patients.
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EP (92.7%, 63.6%, and 84.9%, respectively), P< .001. In
particular, ischemic heart disease was present in 15.3% of VEP,
9.7% in EP, and 5.2% in YP (P= .001). Type II diabetes was
present in 34.3% of VEP, 31.2% in EP, and 14.7% in YP,
P< .001. One hundred nine patients (13.8% of the total) had
liver cirrhosis, and the frequency increased with age (P= .021).
There were no differences between the 3 groups in terms of HBV
or HCV infection and alcohol consumption.
The ASA score was signiﬁcantly higher in VEP: 71.5% of
patients had an ASA score ≥3 compared with 32.3% of EP and
14.0% in YP (P< .001). The CCI was higher in VEP: 57.7% of
patients had CCI ≥3 compared with 50.2% in EP and 27.6% in
YP (P< .001). Surgical outcomes are summarized in Table 2.
There were no differences between the 3 groups in terms of
extension of hepatectomy and type of associated procedures.3.2. Morbidity and mortality
Overall morbidity, severe morbidity (Dindo score≥3), 30-day
mortality and 90-day/in-hospital mortality were 61.8%,
12.3%, 1.0%, and 1.4%, respectively (Table 2). Overall
morbidity was 57.9% in YP, 66.7% in EP and 62.8% in VEP,
and the difference among the groups was not statistically
signiﬁcant (P= .068).
Liver-related complications occurred in 25.9% of the patients
without signiﬁcant differences in the 3 groups. In contrast, the
rate of nonliver-related complications was higher in EP (55.9%)
compare with YP and VEP (46.0% and 46.7%, respectively,
P= .032). Severe complications (Dindo≥3) occurred in 10.6% of3patients <65 years (YP), 12.2% of patients 65 to 74 years (EP),
and 17.5% of patients ≥75 years (VEP) (P= .103). The 30-day
mortality rate and 90-day/in-hospital mortality rate were 0.3%
and 0.3% in YP, 1.1% and 1.4% in EP, and 2.9% and 4.4% in
VEP (P= .022 and P= .002), respectively.
The cause of death of the patient who died in YP was acute
coronary syndrome (ACS). A total of 4 of EP died, 2 deaths were
related to ACS and 2 to PHLF. Six patients died in VEP, 2 for
ACS, 3 for sepsis, and 1 for aspiration pneumonia.3.3. Risk factors of severe morbidity and mortality
Results of the univariate and multivariate analyses of risk factors
associated with severe morbidity are summarized in Table 3.
Presence of any comorbidities, ischemic heart disease, type II
diabetes, cirrhosis,major hepatectomy, bile duct resection, and red
blood cells (RBC) transfusion ≥3U were factors related with a
higher rate of severe morbidity in univariate analysis. In
multivariate analysis, ischemic heart disease (OR 3.005, 95%
CI: 1.514–5.963, P= .002), cirrhosis (OR 2.502, 95% CI:
1.400–4.471, P= .002), major hepatectomy (OR 1.830, 95%
CI: 1.103–3.036,P= .019), biliary tract-associated procedure (OR
1.925,95%CI: 1.010–3.670,P= .047), andRBCtransfusion≥3U
(OR 3.744, 95%CI: 2.239–6.256, P< .001) were conﬁrmed to be
independent factors related with severe morbidity. Age was not
signiﬁcantly related to severe morbidity in univariate or multivari-
ate analysis (OR 1.600, 95% CI: 0.895–2.861, P= .113).
Univariate analysis and multivariate analysis of risk factors
associated with 90-day/in-hospital mortality are summarized in
Table 4.
Table 2
Surgical procedures and outcomes.
Total
(n=803), n (%)
<65 years (YP)
(n=387), n (%)
65–74 years (EP)
(n=279), n (%)
≥ 75 years (VEP)
(n=137), n (%) P
Minor hepatectomy 561 (69.9) 285 (73.6) 185 (66.3) 91 (66.4) .079
Major hepatectomy 242 (30.1) 102 (26.4) 94 (33.7) 46 (33.6) .079
Right extended hepatectomy 41 (5.1) 17 (4.4) 17 (6.1) 7 (5.1) .517
Left extended hepatectomy 44 (5.5) 18 (4.7) 15 (5.4) 11 (8.0) .496
Right hepatectomy 90 (11.2) 43 (11.1) 34 (12.2) 13 (9.5) .549
Left hepatectomy 59 (7.3) 22 (5.7) 24 (8.6) 13 (9.5) .246
Mesohepatectomy 8 (1.0) 2 (0.5) 4 (1.4) 2 (1.5) .362
Associated surgical procedure
Biliary tract 83 (10.3) 35 (9.0) 32 (11.5) 16 (11.7) .509
Colon 54 (6.7) 31 (8.0) 19 (6.8) 4 (2.9) .121
Rectal 16 (2.0) 11 (2.8) 3 (1.1) 2 (1.5) .250
Vascular 19 (2.4) 10 (2.6) 6 (2.2) 3 (2.2) .926
Pancreas 12 (1.5) 8 (2.1) 2 (0.7) 2 (1.5) .419
Other 63 (7.8) 37 (9.6) 17 (6.1) 9 (6.6) .209
Transfusions RBC 220 (29.4) 100 (27.9) 75 (28.6) 45 (35.4) .260
Transfusions FFP 214 (28.6) 91 (25.5) 82 (31.3) 41 (32.00) .151
Overall morbidity 496 (61.8) 224 (57.9) 186 (66.7) 86 (62.8) .068
Liver-related complications 208 (25.9) 90 (23.3) 76 (27.2) 42 (30.7) .193
PHLF 35 (4.4) 18 (4.7) 14 (5.0) 3 (2.2) .384
Biliary ﬁstula 98 (12.2) 38 (9.8) 42 (15.1) 18 (13.1) .118
Ascites 53 (6.6) 22 (5.7) 20 (7.2) 11 (8.0) .569
Abdominal collections 73 (9.1) 36 (9.3) 27 (9.7) 10 (7.3) .716
Sepsis 52 (6.5) 24 (6.2) 19 (6.8) 9 (6.6) .951
Nonliver-related complications 398 (49.6) 178 (46.0) 156 (55.9) 64 (46.7) .032
Pulmonary complications 219 (27.3) 91 (23.5) 91 (32.6) 37 (27.0) .034
Cardiovascular complications 48 (6.0) 15 (3.9) 18 (6.5) 15 (10.9) .010
Acute renal failure 30 (3.7) 8 (2.1) 7 (2.5) 15 (10.9) <.001
Dindo≥3 99 (12.3) 41 (10.6) 34 (12.2) 24 (17.5) .103
Reoperation 13 (1.6) 6 (1.6) 7 (2.5) 0 (0.0) .181
30 days mortality 8 (1.0) 1 (0.3) 3 (1.1) 4 (2.9) .022
90 days/in-hospital mortality 11 (1.4) 1 (0.3) 4 (1.4) 6 (4.4) .002
Hospital stay, median (range) 10 (1–120) 9 (2–67) 10 (1–56) 11 (4–120) <.001
EP= elderly patients, FFP= fresh frozen plasma, PHLF=posthepatectomy liver failure, RBC= red blood cells, VEP= very-elderly patients, YP= young patients.
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type II diabetes, ASA≥3, CCI≥3, cirrhosis, major hepatectomy,
and RBC transfusion≥3U were factors associated with a higher
rate of 90-day/in-hospital mortality in univariate analysis. In
multivariate analysis, ischemic heart disease (OR 5.305, 95%CI:
1.080–26.053, P= .040), cirrhosis (OR 9.628, 95% CI:
1.818–51.004, P= .008), major hepatectomy (OR 5.683, 95%
CI: 1.413–22.851, P= .014), and RBC transfusion ≥3U (OR
5.575, 95% CI: 1.518–19.705, P< .001) were conﬁrmed to be
independent factors associated with increased risk of mortality.
Age and type II diabetes were not signiﬁcantly related tomortality
in multivariate analysis (OR 3.209, CI: 0.816–12.628, P= .095,
and OR 1.555, CI: 0.944–6.470, P= .057, respectively).3.4. Clinical risk scores for severe morbidity and mortality
The variables identiﬁed at multivariate analysis for severe
morbidity (ischemic heart disease, cirrhosis, major hepatectomy,
biliary tract-associated procedure, and RBC transfusion ≥3U)
were chosen to build a score for severe morbidity (SMS). The
SMS was calculated assigning 1 point for the presence of each
predictive variable. Similarly, variable identiﬁed at multivariate
analysis for 90-day/in-hospital mortality (ischemic heart disease,
cirrhosis, major hepatectomy, and RBC transfusion ≥3U) were
chosen to build a score for mortality (MS). Also for MS 1 point
was assigned for the presence of each predictive variable.4The severe morbidity rate increased according to the SMS,
from 4.5% in patients with 0 points, to 14.0% in patients with 1
point, and to 29.3% in patients with ≥2 points, P< .001, ROC
curve analysis showed an AUC of 0.724 (Figs. 1A and 2A). Also,
the 90-day/in-hospital mortality rate increased according to MS,
from 0.0% in patients with 0 points, to 0.7% in patients with 1
point, and to 8.3% in patients with ≥2 points, P< .001. ROC
curve analysis showed an AUC of 0.915 (Figs. 2B and 3A).
Moreover, we applied the 2 scores (SMS and MS) in the
different age intervals (YP, EP, and VEP). We observed no
statistically signiﬁcant differences in severe morbidity or
mortality rates in patients with a score of 0 or 1 point according
to the 3 age intervals. Conversely, for patients with scores ≥2 the
short-term outcome after liver resection were signiﬁcantly worse
in older patients. In particular, severe morbidity rate raised from
24.2% in YP, to 29.3% in EP, and to 40.0% in VEP, respectively,
P= .047 (Fig. 1B). Furthermore, 90-day/in-hospital mortality rate
increased from 2.3% in YP, to 7.0% in EP, and to 22.7% in VEP,
respectively, P= .017 (Fig. 3B).4. Discussion
In our study, major hepatectomy, bile duct resection, periopera-
tive transfusion of 3U or more of RBC, ischemic heart disease,
and cirrhosis were the main factors related with severe morbidity
and 90-day/in-hospital mortality. These results suggest that age is
Table 3
Univariate and multivariate analysis of risk factors associated with severe morbidity (Dindo≥3).
Univariate analysis Multivariate analysis
Severe morbidity, n (%) P Odds ratio 95% CI P
Age
<65 (YP) 41/387 (10.6) .103 1.600 0.895–2.861 .113
65–75 (EP) 34/279 (12.2)
≥75 (VEP) 24/137 (17.5)
Gender
M 64/489 (13.1) .241
F 35/314 (11.1)
ASA
<3 61/561 (10.9) .023 0.799 0.455–1.403 .435
≥3 38/242 (15.7)
Any comorbidities
0 15/193 (7.8) .016
1 84/610 (13.8)
Ischemic heart disease
0 81/735 (11.0) .001 3.005 1.514–5.963 .002
1 18/68 (26.5)
Type II diabetes
0 67/612 (10.9) .025 1.174 0.671–2.054 .575
1 32/191 (16.8)
Pulmonary comorbidities
0 91/757 (12.0) .195
1 8/46 (17.4)
CCI
<3 51/477 (10.7) .056
≥3 48/326 (14.7)
Cirrhosis
0 78/680 (11.5) .020 2.502 1.400–4.471 .002
1 21/109 (19.3)
ICG R15
<10 16/127 (12.6) .444
≥10 8/55 (14.5)
Disease
Benign 10/103 (9.7) .245
Malign 89/700 (12.7)
Extension of hepatectomy
Minor 50/561 (8.9) <.001 1.830 1.103–3.036 .019
Major 49/242 (20.2)
Colon-associated procedure
0 95/749 (12.7) .179
1 4/54 (7.4)
Rectal-associated procedure
0 98/787 (12.5) .393
1 1/16 (6.3)
Biliary tract-associated procedure
0 76/720 (10.6) <.001 1.925 1.010–3.670 .047
1 23/83 (27.7)
Vascular-associated procedure
0 96/784 (12.2) .422
1 3/19 (15.8)
Pancreas-associated procedure
0 96/791 (12.1) .175
1 3/12 (25.0)
Other-associated procedure
0 91/740 (12.3) .525
1 8/63 (12.7)
Transfusion RBC ≥3U
0 60/641 (9.4) <.001 3.744 2.239–6.256 <.001
1 36/111 (32.4)
ASA score=American society of Anesthesiologists’ score, CCI=Charlson comorbidity index, EP=elderly patients, ICG R15= indocyanine green retention rate after 15minutes, RBC= red blood cells, VEP=
very-elderly patients, YP= young patients.
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Table 4
Univariate and multivariate analysis of risk factors associated with 90-day/in-hospital mortality.
Univariate analysis Multivariate analysis
Mortality, n (%) P Odds ratio 95% CI P
Age
<65 (YP) 1/387 (0.3) .002 3.209 0.816–12.628 .095
65–75 (EP) 4/279 (1.4)
≥75 (VEP) 6/137 (4.4)
Gender
M 10/489 (2.0) .058
F 1/314 (0.3)
ASA
<3 4/561 (0.7) .021 0.979 0.169–5.656 .981
≥3 7/242 (2.9)
Any comorbidities
0 0/193 (0.0) .048
1 11/610 (1.8)
Ischemic heart disease
0 7/735 (1.0) .010 5.305 1.080–26.053 .040
1 4/68 (5.9)
Type II diabetes
0 5/612 (0.8) .026 1.555 0.944–6.470 .057
1 6/191 (3.1)
Pulmonary comorbidities
0 9/757 (1.2) .127
1 2/46 (4.3)
CCI
<3 3/477 (0.6) .031 0.444 0.370–5.280 .520
≥3 8/326 (2.5)
Cirrhosis
0 6/680 (0.9) .011 9.628 1.818–51.004 .008
1 5/109 (4.6)
ICG R15
<10 4/127 (3.1) .523
≥10 1/55 (1.8)
Disease
Benign 0/103 (0.0) .219
Malign 11/700 (1.6)
Extension of hepatectomy
Minor 4/561 (0.7) .021 5.683 1.413–22.851 .014
Major 7/242 (2.9)
Colon-associated procedure
0 11/749 (1.5) .463
1 0/54 (0.0)
Rectal-associated procedure
0 10/787 (1.3) .200
1 1/16 (6.3)
Biliary tract-associated procedure
0 8/720 (1.1) .096
1 3/83 (3.6)
Vascular-associated procedure
0 11/784 (1.4) .767
1 0/19 (0.0)
Pancreas-associated procedure
0 11/791 (1.4) .846
1 0/12 (0.0)
Other-associated procedure
0 11/740 (1.5) .405
1 0/63 (0.0)
Transfusion RBC ≥3U
0 1/641 (0.1) <.001 5.575 1.518–19.705 <.001
1 10/111 (9.0)
ASA score=American society of Anesthesiologists’ score, CCI=Charlson comorbidity index, EP=elderly patients, ICG R15= indocyanine green retention rate after 15minutes, RBC= red blood cells, VEP=
very-elderly patients, YP= young patients.
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Figure 1. Frequency of severe morbidity (Dindo≥3) rate according to the
SevereMorbidity Score (SMS). For each of the following variables was assigned
1 point: ischemic heart disease, cirrhosis, major hepatectomy, biliary tract-
associated procedure, and transfusion of RBC≥3U. (A) Univariate analysis of
severe morbidity rate comparing patients with 0, 1, or ≥2 points; (B) univariate
analysis of severemorbidity rates in patients with 0, 1, or≥2 points according to
the different age interval. YP, young patients, <65 years; EP, elderly patients,
65–74 years; VEP, very-elderly patients, ≥75 years.
Figure 2. Receiver operating characteristic (ROC) curves of Severe Morbidity Sco
ability of SMS and MS to predict severe morbidity and 90-day/in-hospital mortal
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7not a contraindication for liver resection. However, postopera-
tive outcomes were worse among VEP (≥75 years) who
underwent aggressive surgery, such as major hepatectomy, bile
duct resection, those who required perioperative transfusion of 3
U or more of RBC, or with severe preexisting comorbidities, such
as ischemic heart disease and cirrhosis. These ﬁndings have
clinical relevance considering the growing number of EP and VEP
with liver malignancies who require complex surgical procedures.
The rate of EP included in surgical series is increasing steadily
because of the prolonged mean age of the population and the
improvements in the perioperative management.[1–3] However, in
several surgical series, advanced age has been related to a higher
risk of postoperative morbidity and mortality.[4,10]
In the existing literature, there is a lack of agreement regarding
the deﬁnition of elderly making it difﬁcult to compare the results
of the different studies. Therefore, the identiﬁcation of patients at
higher risk can be useful to select surgical candidates more
accurately. Additionally, preoperative treatments can be planned
to decrease the risks associated with surgery.
Commonly, the number of comorbidities increases with age.
In our study, the incidence of ischemic heart disease,
hypertension, type II diabetes, and pulmonary comorbidities
was signiﬁcantly higher in EP and VEP compared with YP. The
number and severity of comorbidities increased with age;
accordingly, ASA score and CCI were proportionally higher
with age. Further, these ﬁndings are consistent with those of
previous studies.[4,10] Moreover, cirrhosis was signiﬁcantly more
frequent in patients older than 75 years. Nevertheless, liver
function assessed with common blood test and ICG R15 test was
similar across the 3 groups.
Indications for surgery were signiﬁcantly different between
groups. Malignant diseases were a more common surgical
indication in EP andVEP comparedwith YP (94.3%, 91.2%, and
80.6%, P< .001), respectively. There were no signiﬁcant differ-
ences in the type of hepatectomy and associated surgical
procedures among the 3 groups.
Experimental studies have demonstrated that aging is related
to a reduction of liver volume, portal blood ﬂow,[13,26] and an
overall reduction of HB functions.[27] Moreover, liver regenera-
tion following injury or partial resection seems to be decreased
with age.[28,29]re (SMS) (A) and Mortality Score (MS) (B). Curves represent the performances
ity, respectively.
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Figure 3. Frequency of 90-day/in-hospital mortality rate according to the
Mortality Score (MS). For each of the following variables was assigned 1 point:
ischemic heart disease, cirrhosis, major hepatectomy and transfusion of
RBC≥3U. (A) Univariate analysis of 90-day/in-hospital mortality rate
comparing patients with 0, 1, or ≥2 points; (B) univariate analysis of 90-
day/in-hospital mortality rates in patients with 0, 1, or ≥2 points according to
the different age interval. YP, young patients, <65 years; EP, elderly patients,
65–74 years; VEP, very-elderly patients, ≥75 years.
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of postoperative complications among EP after major hepatecto-
my as reported in past clinical studies. In fact, in the 1990s the
reported mortality rate after major hepatectomy was as high as
11.1%, with a cut-off value of 65 years.[30] A case–control study
that compared liver regeneration after portal vein occlusion
(PVO) in patients older or younger than 70 years demonstrated
that liver regeneration is not signiﬁcantly affected by age.[14]
Recent clinical surgical series conﬁrmed these data, showing
similar short-term outcomes between elderly and younger
patients after liver resection.[4,7,9] Reddy et al analyzed 856
patients who underwent major hepatectomy in 2 high-volume
centers and concluded that each 1- and 10-year increase in age
resulted in odds ratios of postoperative mortality of 1.036 (95%
CI: 1.003–1.071, P= .034) and 1.426 (95% CI: 1.026–1.982,
P= .034), respectively. In this study, however, the mortality rate
for patients over 75 years and between 65 and 74 years was the
same (8.4%). It was 7.0% in patients from 50 to 64 years, and
was signiﬁcantly decreased only in patients younger than 50 years
(1.5%). Moreover, increasing age was associated with postoper-
ative sepsis, but not with overall postoperative morbidity.[2]8Another large series reported by Adam et al analyzed the data
from a multicenter registry of patients with CRLM who
underwent liver resection. The study included 7764 patients
and showed that the postoperative mortality was signiﬁcantly
more common in patients older than 70 years (3.8% vs 1.6%,
P< .001).[31]
In our study, the mortality rate showed an increase with age:
0.3% in YP, 1.4% in EP, and 4.4% in VEP. However, in
multivariate analysis, age was not signiﬁcantly related to
increased mortality, suggesting that other factors can also
inﬂuence postoperative outcomes.
In the literature, the relationship between postoperative
morbidity and age has not been investigated extensively. A
recent study by Schiergens et al analyzed outcomes of elective
liver resection in 879 patients between 2003 and 2012. Patients
were stratiﬁed into 3 age cohorts: >70 years, 60 to 69 years, and
<60 years. The 30-daymortality rate of all patients was 8%,with
a statistically signiﬁcant difference between the groups: 14% in
patients >70 years, 7% in patients 60 to 69 years, and 5% in the
younger group, P= .001. The incidence of severe morbidity
(P< .01) and nonsurgical complications (P< .001) was higher in
older patients compared with younger ones. Moreover, this study
showed that blood loss and presence of comorbidities, based on a
CCI>2, were factors related to an increased risk of postoperative
morbidity. However, that study did not report an analysis of
factors related to postoperative mortality.[10]
In the present study, we performed an extensive analysis of
factors related to severe morbidity and with 90-day/in-hospital
mortality to improve the safety and feasibility of HB surgery for
EP. According to our results, the short-term outcomes of liver
resection were related to the type of surgical procedure (major
hepatectomy, biliary tract-associated procedure), complexity of
surgical procedure (RBC transfusions), presence of underlying
liver diseases (cirrhosis), and presence of comorbidities (ischemic
heart disease).
Moreover, in our study, we proposed simple and reliable scores
for severe morbidity (SMS) and for 90-day/in-hospital mortality
(MS) based on the variables identiﬁed by multivariate analysis.
The severe morbidity rate increased according to the SMS, from
4.5% in patients awarded with 0 points, to 14.0% in patients
with 1 point, and to 29.3% in patients with ≥2 points, P< .001
(Fig. 1A). Also, the 90-day/in-hospital mortality rate increased
according to MS, from 0.0% in patients awarded with 0 points,
to 0.7% in patients with 1 point, and to 8.3% in patients with ≥2
points, P< .001 (Fig. 3A).
Furthermore, age seem to be related with a signiﬁcant
increasing of the risk of severe morbidity and mortality only
in patients with a SMS and MS ≥2, respectively.
In particular, severe morbidity rate raised from 24.2% in YP,
to 29.3% in EP, and to 40.0% in VEP, respectively, P= .047
(Fig. 1B), and also 90-day/in-hospital mortality rate increased
from 2.3% in YP, to 7.0% in EP, and to 22.7% in VEP,
respectively, P= .017 (Fig. 3B).
A previous study by Breitenstein et al proposed a simple
method to assess the risk of severe complications (Dindo≥3) after
liver resection. Four clinical factors were identiﬁed as indepen-
dent predictors of severe complications, including ASA score,
preoperative aspartate aminotransferase serum level, major
hepatectomy, and the need for associated extrahepatic procedure.
A prediction score was calculated for the study population of
369 patients using the 4 independent predictive variables ranging
from 0 to 10 points. The risk of developing severe complications
was 16% in “low-risk” patients (0–2 points), 37% in
[9] Tsujita E, Utsunomiya T, Yamashita Y, et al. Outcome of hepatectomy in
Ruzzenente et al. Medicine (2017) 96:20 www.md-journal.com“intermediate-risk” patients (3–5 points), and 60% in “high-
risk” patients (6–10 points).[32] Although these results were
interesting, the results were not stratiﬁed according to age groups.
Several limitations should be considered when interpreting
present study. We analyzed a large series of 803 consecutive
patients underwent liver surgery but the statistical analysis
conducted may result subobtimal, in particular, due to the
relatively low rate of postoperative mortality rate (1.4%, n=11
patients). Another limitation of the study could be its retrospec-
tive nature.
In our study, we found that age per se is not a contraindication
for liver surgery. However, VEP have increased postoperative
severe morbidity and mortality, particularly when multiple risk
factors are present. The proposed scoring system and multidisci-
plinary approach should be applied to obtain an accurate
preoperative selection of patients in order to improve the
postoperative outcomes. Moreover, preoperative and intraoper-
ative management should aim to reduce blood loss as much as
possible because this was one of the major negative factors.
Nevertheless, our results should be conﬁrmed and validated with
larger series by other institutions.5. Conclusion
In conclusion, we conducted a study that investigated the clinical
variables and postoperative outcomes of patients who underwent
liver resection according to 3 age intervals. Age alone should not
be considered a contraindication for hepatectomy. Liver resection
in EP can be safely performed by both an accurate patient
selection and a careful surgical strategy. We identiﬁed clinical
factors that can be useful to stratify the risk of postoperative
severe morbidity and mortality. The scores proposed (SMS and
MS) are simple tools that can be useful to stratify the risk of
morbidity and mortality after hepatectomy. Moreover, severe
morbidity and mortality increases according to the different age
intervals in patients with scores ≥2.
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